湖北济川药业股份有限公司 三、公司将按照有关规定及时向中国证券登记结算有限责任公司上海分公司 申请办理限制行权相关事宜。 证券代码：600566 证券简称：济川药业 公告编号： 2026-013 关于 2022 年限制性股票与股票期权激励计划 首次授予股票期权限制行权期间的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据《上市公司股权激励管理办法》《上海证券交易所上市公司自律监管指 南第 2 号——业务办理》《湖北济川药业股份有限公司 2022 年限制性股票与股票 期权激励计划》及中国证券登记结算有限责任公司上海分公司关于股票期权自主 行权的相关规定，并结合湖北济川药业股份有限公司（以下简称"公司"）2025 年年度报告及 2026 年第一季度报告披露计划，现对公司 2022 年限制性股票与股 票期权激励计划首次授予股票期权自主行权时间进行限制，具体情况如下： 一、公司 2022 年限制性股票与股票期权激励计划首次授予股票期权第一个 行权期（期权代码：1000000228）实际可行权期间为 2025 年 10 ...

S1130525060003 gantanhuan gjzq.com.cn 投资逻辑 受国际石油价格持续上涨及海外能源成本较高的影响，各类化工产品普遍迎来明显涨价，其中溶剂类产品由于其较难 囤货，市场报价持续走高，成为本轮化工品涨价中弹性最显著的品类之一，也直接带动医药中间体、原料药等下游行 业成本抬升。受到上游原材料成本提升影响，下游原料药产品或将迎来提价契机。从供给端看，由于原料药行业在 2020- 2022 年集中扩产，预计供给压力仍然存在，价格有望缓慢传导。从需求端看，下游客户自 23 年 4 月去库存，目前客 户库存水平已长时间处于较低位置。原料药价格已在低位运行较长时间，客户库存水平较低，一旦提价后预计会有较 好持续性，后续可关注价格提升带来的利润弹性。 药品：3 月 20 日，诺华宣布以 20 亿美元预付款及最高 10 亿美元里程碑付款，收购 Synnovation Therapeutics 旗下 泛突变选择性 PI3Kα抑制剂 SNV4818 及相关项目组合，强化 PI3Kα靶点差异化布局，聚焦突变选择性抑制剂在 HR+/HER2-乳腺癌领域的联用潜力，国内建议关注和黄医药 PI3K-ATTC ...

湖北济川药业股份有限公司 证券代码： 600566 证券简称： 济川药业 公告编号： 2026-012 关于全资子公司利用闲置募集资金 进行现金管理的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 履行的审议程序：湖北济川药业股份有限公司（以下简称"公司"）于 2025 年 4 月 25 日召开第十届董事会第十四次会议，于 2025 年 5 月 16 日召开 2024 年年度股东大会，审议通过了《关于全资子公司利用闲置募集资金和自有资金进 行现金管理的议案》，同意公司在不影响募投项目正常实施并保证募集资金安全 的前提下，使用额度不超过 5.8 亿元（含本数）的闲置募集资金进行现金管理， 投资对象为安全性高、流动性好、有保本约定、投资期限不超过 12 个月的投资 产品，包括但不限于理财产品、结构性存款、定期存款、大额存单等。具体内容 详见公司分别于 2025 年 4 月 26 日、2025 年 5 月 17 日披露于上海证券交易所网 站（http://www.sse.com.cn）的相关公告。 特别风险 ...

证券代码：600566 证券简称：济川药业 公告编号：2026-011 一、回购股份的基本情况 湖北济川药业股份有限公司关于 以集中竞价交易方式回购股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2025/11/25 | | --- | --- | | 回购方案实施期限 | 待董事会审议通过后 12 个月 | | 预计回购金额 | 2,500万元~5,000万元 | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 □用于转换公司可转债 | | | □为维护公司价值及股东权益 | | 累计已回购股数 | 934,700股 | | 累计已回购股数占总股本比例 | 0.10% | | 累计已回购金额 | 25,000,953元 | | 实际回购价格区间 | 25.94元/股~27.49元/股 | 公司于 2025 年 11 月 24 日召开了第十届董事会第十九次会议，审议通过了《关 于以集中竞价交易方式回购公司股份方案的议案》，同意公司使用自有资金通过集 中 ...

Investment Rating - The industry investment rating is "stronger than the market" (预计6个月内，行业指数表现强于市场表现5%以上) [32] Core Insights - Jichuan Pharmaceutical has secured exclusive commercialization rights for the drug Bimekizumab (brand name: Zeli Mei) in mainland China, excluding Hong Kong, Macau, and Taiwan, with a total payment not exceeding RMB 190 million (including tax) [3][13] - Bimekizumab is the first approved treatment for eczema in children aged 2 and above, acting as an aromatic hydrocarbon receptor (AhR) modulator to suppress inflammation and repair skin barriers [3][13] - The product is expected to be approved for market launch in November 2024 and currently is not included in the National Basic Medical Insurance Drug List, indicating it is in the early stages of market expansion [3][13] Summary by Sections Industry Viewpoints - The report emphasizes the continuous improvement of global competitiveness among Chinese innovative pharmaceutical companies, suggesting a focus on potential treatment areas such as metabolic diseases, chronic diseases, and central nervous system disorders [4] - It also highlights emerging technology platforms like small nucleic acid drugs and CAR-T therapies, recommending companies such as Baiji Shenzhou and Dongcheng Pharmaceutical for investment [4] Industry News - Jichuan Pharmaceutical's acquisition of Bimekizumab is noted as a significant development in the biopharmaceutical sector, providing a new treatment option for eczema [7][13] - GSK's acquisition of 35Pharma for $950 million to gain access to a new pulmonary arterial hypertension drug is also highlighted, showcasing ongoing consolidation in the industry [14] - GSK's submission of a new hepatitis B drug, Bepirovirsen, for market approval in Japan is mentioned, indicating advancements in chronic hepatitis treatment [16][17] - The approval of a new JAK/ROCK inhibitor by Zhengda Tianqing for treating primary myelofibrosis is noted, reflecting innovation in hematological therapies [18] Market Performance - The pharmaceutical sector saw a 0.50% increase last week, while the Shanghai and Shenzhen 300 Index rose by 1.08%, ranking 21st among 28 industries [8][20] - The Hong Kong pharmaceutical sector experienced a decline of 6.07%, with the Hang Seng Index down by 1.93%, ranking 11th among 11 industries [31]

Core Viewpoint - The independent directors of Hubei Jichuan Pharmaceutical Co., Ltd. are set to resign as their term approaches the six-year limit, which may affect the composition of the board [1][2]. Group 1: Independent Directors' Tenure - The current independent directors, Mr. Yao Hong and Mr. Lu Chaojun, have served since March 2, 2020, and their tenure will reach six years soon [1]. - Both directors have applied to resign from their positions on the board and its committees, and will not hold any positions in the company after their resignation [1]. Group 2: Board Composition and Transition - The resignation of the two independent directors will result in the number of independent directors falling below one-third of the total board members [1]. - The company is in the process of preparing for the board's re-election, which is scheduled to be completed before the current board's term ends in May 2026 [1].

Group 1 - Shanghai Zedman Pharmaceutical Technology Co., Ltd. has signed an agreement with Jichuan Pharmaceutical Co., Ltd. for exclusive commercialization rights of Zeli Mei in China (excluding Hong Kong, Macau, and Taiwan), with a maximum upfront payment of 190 million yuan and milestone payments [1] - The collaboration is a significant milestone for Zedman in market expansion and resource complementarity, aiming to invigorate pediatric and dermatological drug offerings [1] - Zeli Mei is the first approved AhR modulator for treating eczema in children over 2 years old and adults, addressing clinical pain points of traditional treatments [2] Group 2 - Zedman Pharmaceutical's CEO emphasizes the importance of this collaboration for maximizing the innovative value of Zeli Mei and accelerating its internationalization [2] - Jichuan Pharmaceutical's General Manager highlights the strategic partnership as a key enhancement in pediatric and dermatological treatment product layout, filling a clinical gap for young eczema patients [3] - The partnership aims to leverage Jichuan's established sales network and academic promotion team to expedite the market introduction and clinical adoption of Zeli Mei [3]

Group 1 - Shanghai Zedman Pharmaceutical Technology Co., Ltd. has signed an agreement with Jichuan Pharmaceutical Co., Ltd. for the exclusive commercialization rights of Zeli Mei® in China (excluding Hong Kong, Macau, and Taiwan), with a maximum upfront payment of 190 million yuan, including 125 million yuan upfront and 65 million yuan in milestone payments [2] - Zeli Mei® is a non-hormonal innovative drug developed by Zedman, recognized as the first approved AhR modulator for treating eczema in children over 2 years old and adults, addressing clinical pain points of traditional treatments [3] - The collaboration is seen as a significant milestone for Zedman in market expansion and resource complementarity, aiming to enhance pediatric and dermatological treatments in China [2][3] Group 2 - Zedman’s CEO emphasized the importance of this partnership in maximizing the innovative value of Zeli Mei® and accelerating its internationalization process [3] - Jichuan Pharmaceutical's General Manager highlighted that this collaboration strengthens their product portfolio in pediatric and dermatological treatments, showcasing the strength of Chinese innovation in the dermatology field [3]

Group 1 - Shanghai Zedman Pharmaceutical Technology Co., Ltd. has signed an agreement with Jichuan Pharmaceutical Co., Ltd. for exclusive commercialization rights of Zeli Mei in China, excluding Hong Kong, Macau, and Taiwan [1] - Zedman will receive a maximum of 190 million yuan in upfront and milestone payments, including a maximum of 125 million yuan upfront and 65 million yuan for research milestones [1] - This collaboration marks a significant milestone in Zedman's market expansion and is a strategic move for resource complementarity and mutual benefits [1] Group 2 - Zeli Mei (Bimodamide Cream) is an innovative non-hormonal drug developed by Zedman, approved for treating eczema in children over 2 years old and adults, representing the first AhR modulator for this indication [2] - The drug works by suppressing inflammation, repairing skin barriers, regulating microbiota, and combating oxidative stress, addressing clinical pain points of traditional treatments [2] - Zedman’s CEO emphasized the importance of this partnership for maximizing the innovative value of Zeli Mei and accelerating its market promotion and clinical application in China [2] Group 3 - Jichuan Pharmaceutical's General Manager highlighted that this collaboration strengthens their product layout in pediatric and dermatological treatments, filling a clinical gap for young patients with eczema [2] - The partnership aims to leverage Jichuan's established sales network and specialized academic promotion team to expedite Zeli Mei's market entry and clinical adoption [2] - This initiative will enhance Jichuan's product matrix in pediatrics and dermatology, contributing to the development of skin health for children and adults in China [2]

鉴于公司第十届董事会将于2026年5月任期届满，公司董事会换届工作尚在 筹备中。姚宏先生、卢超军先生任期届满离任将导致公司独立董事人数少于董事 会成员三分之一。根据相关法律法规和《公司章程》的规定，在董事会换届工作 完成以前，姚宏先生、卢超军先生将继续履行其独立董事及相关董事会专门委员 会委员职责，直至公司股东会选举产生新的独立董事。 特此公告！ 湖北济川药业股份有限公司董事会 2026 年 2 月 28 日 证券代码： 600566 证券简称： 济川药业 公告编号： 2026-010 湖北济川药业股份有限公司 关于部分独立董事任期届满的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据《上市公司独立董事管理办法》等相关规定，独立董事在上市公司连续 任职时间不得超过六年。湖北济川药业股份有限公司（以下简称"公司"）现任 独立董事姚宏先生、卢超军先生自2020年3月2日起在公司担任独立董事，连任公 司独立董事时间即将达到六年。因此，姚宏先生、卢超军先生申请辞去公司第十 届董事会独立董事以及在董事会各专门委员会中担任 ...